🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06341062
Recruiting Observational

The Application of Contrast-enhanced Ultrasound in Acute Kidney Injury in ICU

NCT06341062 · tracked via the Priya Life Science China tracker
Phase
Observational
Started
2024-04-15
Last updated
2025-02-17

Condition(s) studied

Intensive Care UnitAcute Kidney InjuryUltrasound

Investigational drug(s) / intervention(s)

Renal microcirculation quantitatively assessed by Contrast-enhanced ultrasound

Renal microcirculation quantitatively assessed by Contrast-enhanced ultrasound: Renal microcirculation quantitatively assessed by Contrast-enhanced ultrasound before hospital discharge

Study summary

The goal of this study is to quantitatively assess renal microcirculation changes by contrast-enhanced ultrasound and to obtain systemic hemodynamic information by ultrasound Doppler at the same time, to analyze the relationship between renal microcirculation changes and systemic hemodynamic changes, and to explore its predictive value in renal function recovery in patients with critical acute kidney injury. The main questions it aims to answer are:

1. To explore the quantitative parameters of contrast-enhanced ultrasound which can reflect the changes of renal microcirculation.
2. To explore the relationship between renal microcirculation and systemic hemodynamics.
3. To explore the value of renal microflow changes quantitatively evaluated by contrast-enhanced ultrasound in predicting renal function recovery.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age \>18 years old; * AKI was diagnosed \< 24 hours after first admission to intensive care unit (ICU) and the expected length of stay in ICU ≥48 hours; * Meet Kidney Disease Improving Global Outcomes (KDIGO) 2012 diagnostic criteria for acute kidney injury; * Contrast-enhanced ultrasound was performed within 24 hours after diagnosis of acute kidney injury (AKI). Exclusion Criteria: * Known severe chronic kidney disease (CKD≥ stage 4) or undergoing hemodialysis treatment; * Kidney transplantation or renal malignancy; * Terminal stage of malignant tumor; * Pregnancy; * Renal artery stenosis or renal vein thrombosis; * Allergy to contrast agent SonoVue(BraccoSpA, Milan, Italy) or its components, or the presence of severe cardiopulmonary insufficiency (e.g., right-to-left shunt heart disease or pulmonary systolic blood pressure \>90mmHg).

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Department of Ultrasound Diagnosis, Peking University Third Hospital Beijing Beijing Municipality Recruiting

More Peking University Third Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06341062 on ClinicalTrials.gov ↗ ← All trials in China